These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7295193)

  • 1. Fibrinogen catabolism in patients with type II and type IV hyperlipidemia. Effect of dietary and clofibrate treatment on laboratory findings.
    Fletcher A; Alkjaersig N; Schonfeld G; Witztum J
    Arteriosclerosis; 1981; 1(3):202-9. PubMed ID: 7295193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
    Vessby B; Lithell H; Gustafsson IB; Borberg J
    Atherosclerosis; 1979 Aug; 33(4):457-77. PubMed ID: 228684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased excretion of fecal fat in hyperlipidemic patients.
    Nagasaki A; Maruhama Y
    Tohoku J Exp Med; 1980 May; 131(1):99-100. PubMed ID: 7404579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clofibrate and tiadenol treatment in hyperlipoproteinemias. A comparative trial of drugs affecting lipoprotein catabolism and biosynthesis.
    Sirtori M; Montanari G; Gianfranceschi G; Malacrida MG; Battistin P; Morazzoni G; Tremoli E; Colli S; Maderna P; Sirtori CR
    Atherosclerosis; 1983 Nov; 49(2):149-61. PubMed ID: 6365105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The concentration of high density lipoprotein in patients with type IV hyperlipoproteinemia and the effect of clofibrate.
    Brook JG; Lavy A; Aviram M; Zinder O
    Atherosclerosis; 1980 Aug; 36(4):461-9. PubMed ID: 7417365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of clofibrate on lipid and protein components of very low density lipoproteins in type IV hyperlipoproteinaemia.
    Naruszewicz M; Szostak WB; Cybulska C; Kozłowska M; Chotkowska E
    Atherosclerosis; 1980 Apr; 35(4):383-92. PubMed ID: 7378119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
    Bolzano K; Krempler F; Schellenberg B; Schlierf G
    Acta Med Austriaca; 1979; 6(3):90-4. PubMed ID: 547652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with bezafibrate.
    Schubotz R; Schneider J; Hausmann L; Mühlfellner G; Mühlfellner O; Kaffarnik H
    Artery; 1980; 8(6):553-9. PubMed ID: 7259534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
    Schwartzkopff W; Schilling A; Calder D
    Med Welt; 1980 Apr; 31(14):515-20. PubMed ID: 7374415
    [No Abstract]   [Full Text] [Related]  

  • 10. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].
    Arntz HR; Klemens UH; Vollmar LJ; Lang PD
    Med Klin; 1978 Dec; 73(49):1731-7. PubMed ID: 723760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate.
    Rössner S; Orö L
    Atherosclerosis; 1981; 38(3-4):273-82. PubMed ID: 7225166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia.
    Vecchio TJ; Linden CV; O'Connell MJ; Heilman J
    Arch Intern Med; 1982 Apr; 142(4):721-3. PubMed ID: 7073415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia.
    Hunninghake DB; Probstfield JL; Crow LO; Isaacson SO
    Metabolism; 1981 Jun; 30(6):605-9. PubMed ID: 7231197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
    Kokot F; Szczechowska E
    Z Gesamte Inn Med; 1981 Jul; 36(13):454-7. PubMed ID: 7025475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
    Stuyt PM; Stalenhoef AF; Demacker PN; Van 't Laar A
    Atherosclerosis; 1985 Apr; 55(1):51-62. PubMed ID: 3924065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
    Lopez Rodriguez J; Martorell J
    Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of phenofibrate on the blood serum lipid level in hyperlipoproteinemias and its comparison with clofibrate].
    Sznajderman M
    Pol Arch Med Wewn; 1980 Jun; 63(6):543-9. PubMed ID: 7402954
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of clofibrate on intravascular coagulation in hyperlipoproteinemia.
    Carvalho AC; Lees RS; Vaillancourt RA; Colman RW
    Circulation; 1977 Jul; 56(1):114-8. PubMed ID: 301067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia.
    Hunninghake DB; Bell C; Olson L
    Metabolism; 1981 Jun; 30(6):610-5. PubMed ID: 7231198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.